A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
National Institutes of Health Clinical Center (CC)
Newave Pharmaceutical Inc
MacroGenics
UNC Lineberger Comprehensive Cancer Center
Stanford University
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center